- StageZero Life Sciences (TSX:SZLS) will collaborate with My One Medical Source (MOMS) to offer the company’s portfolio of diagnostics to treat MOMS’s customer base
- This includes the company’s Aristotle and AVRT platforms
- MOMS has more than 1,000 medical access points across the United States
- Shares of StageZero Life Sciences are up 10 per cent to C$0.055 as of 11:49 am ET
StageZero Life Sciences (TSX:SZLS) has announced a collaboration with My One Medical Source (MOMS).
The company stated in a news release it will offer its portfolio of diagnostics to treat MOMS’s customer base, including its Aristotle and AVRT platforms.
The Aristotle platform is the first mRNA multi-cancer panel that can screen for multiple cancers with just a single sample of blood. It uses mRNA technology that can identify the molecular signatures of many different kinds of cancers.
StageZero Life Sciences’ AVRT is a physician-led, telehealth program that identifies and manages the early warning signs of cancer and chronic disease.
MOMS has more than 1,000 medical access points across the United States that connect providers, employers and patients with clinical laboratories.
“Coupled with the CareOncology clinical group providing clinical oversight, and via telehealth, we can cater to all 50 states and actively engage with the MAPS and their customer base, as well as draw in new patients. The new programs we are introducing continue to enhance our visibility,” James Howard-Tripp, CEO of StageZero Life Sciences, said in a statement.
MOMS is a platform that connects patients with urgent care centres, pharmacies and private test sites for sample collection. More than 13 billion tests are performed in more than 250,000 laboratories each year.
StageZero Life Sciences is focused on improving the early detection and management of cancer and other chronic diseases.
Shares of StageZero Life Sciences are up 10 per cent to C$0.055 as of 11:49 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the StageZero Life Sciences Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.